Financial Performance - The company's operating revenue for the first quarter was RMB 179,906,064, representing a year-on-year increase of 21.85% compared to RMB 147,647,109 in the same period last year[5]. - Net profit attributable to shareholders was RMB 2,665,114, reflecting a growth of 13.53% from RMB 2,347,396 in the previous year[5]. - Net profit for Q1 2025 was RMB 2,581,403, compared to RMB 2,259,878 in Q1 2024, showing a growth of 14.2%[20]. Cash Flow - The net cash flow from operating activities decreased significantly by 84.34%, amounting to RMB 6,880,311, down from RMB 43,938,388 in the same period last year[5][10]. - For the first quarter of 2025, the net cash flow from operating activities was RMB 6,880,311, a decrease of 84.7% compared to RMB 43,938,388 in the first quarter of 2024[21]. - Total cash inflow from operating activities was RMB 238,939,006, down 2.9% from RMB 244,729,122 in the same period last year[21]. - Cash outflow from operating activities increased to RMB 232,058,695, up 15.5% from RMB 200,790,734 in the first quarter of 2024[21]. - The net cash flow from investing activities was -RMB 283,810,018, compared to -RMB 3,807,572 in the first quarter of 2024, indicating a significant increase in cash outflow[21]. - Cash inflow from investing activities totaled RMB 591,051,753, a decrease of 35.6% from RMB 919,724,441 in the previous year[21]. - Cash outflow from investing activities was RMB 874,861,771, down 5.3% from RMB 923,532,013 in the first quarter of 2024[21]. - The net cash flow from financing activities was -RMB 2,005,026, compared to -RMB 2,669,076 in the first quarter of 2024[21]. - The ending cash and cash equivalents balance was RMB 777,319,430, a decrease of 37.0% from RMB 1,233,394,449 at the end of the first quarter of 2024[21]. - The company received RMB 8,367,074 in other cash related to operating activities, an increase of 121.5% from RMB 3,769,626 in the first quarter of 2024[21]. - The company reported a cash flow impact from foreign exchange fluctuations of -RMB 31,466, compared to a positive impact of RMB 36,712 in the first quarter of 2024[21]. Research and Development - Research and development expenses totaled RMB 84,068,447, which is an increase of 31.00% compared to RMB 64,173,693 from the previous year[5][10]. - The ratio of R&D investment to operating revenue increased to 46.73%, up by 3.27 percentage points from 43.46% in the previous year[8]. - R&D expenses rose to RMB 84,068,447 in Q1 2025, compared to RMB 63,616,910 in Q1 2024, indicating a focus on innovation and product development[20]. Assets and Liabilities - Total assets at the end of the reporting period were RMB 2,531,022,514, a decrease of 2.14% from RMB 2,586,502,623 at the end of the previous year[8]. - The total assets as of March 31, 2025, amounted to RMB 2,531,022,514, a decrease from RMB 2,586,502,623 as of December 31, 2024[19]. - Total liabilities decreased to RMB 223,197,709 as of March 31, 2025, down from RMB 281,225,518 at the end of 2024[19]. - The total equity attributable to shareholders reached RMB 2,307,198,823 as of March 31, 2025, slightly up from RMB 2,304,567,412 at the end of 2024[19]. Shareholder Information - The company reported a total of 19,246 common shareholders at the end of the reporting period[13]. - The top ten shareholders held a combined total of 1,339,000,000 shares, representing significant ownership concentration[14]. Government Subsidies and Market Strategy - The company received government subsidies amounting to RMB 4,538,759, which are closely related to its normal business operations[7]. - The company plans to adjust its sales strategies and pricing for the drug Libao Duo® in response to changes in the national drug procurement landscape starting April 2025[17]. - The company is focusing on optimizing its marketing network and customer base in light of provincial medical insurance policies[17]. Credit Impairment - The company reported a significant increase in credit impairment losses, amounting to RMB 14,720,951 in Q1 2025, compared to a reversal of RMB 5,559,028 in Q1 2024[20].
复旦张江(01349) - 2025 Q1 - 季度业绩